A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization

Sponsor
Hoffmann-La Roche
Study ID
NCT06503250
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    Observational Study
  • Bevacizumab — DRUG
    Observational Study
  • Transarterial Chemoembolization — RADIATION
    Observational Study

Study Details

This is a multicenter, retrospective, observational cohort study to describe the effectiveness and safety of Atezo+Bev plus Transarterial Chemoembolization (TACE) among adult patients with unresectable hepatocellular carcinoma (HCC) in real-world clinical practice in China. Eligible patients diagnosed with unresectable HCC initiating the Atezo+Bev and TACE between 28 October 2020 and 31 December 2023 will be included in this study.

Key Dates

Start date
Jul 19, 2024
Status verified
Mar 2025
Primary completion
Nov 27, 2024
Completion
Nov 27, 2024

Study Design

Enrollment
113 participants (actual)

Arms

  • Arm: Retrospective Cohort
    Secondary data from medical records of approx 5 sites across China will be utilized. Patient identification period is between 28 Oct 2020 to 31 Dec 2023. The index date is defined as the earlier date of initiating Atezo+Bev or TACE after the initial diagnosis of unresectable HCC. Baseline period is defined as 60 days prior to the index date. Observation period is defined as the period from the index date until death, latest visit record during retrospective observation period, diagnosis of other primary cancer (except basal cell carcinoma), or 31 March 2024, whichever occurs first.

Primary Outcome Measure

Median Time to Real-World Progression-Free Survival (rwPFS) [ Time Frame: up to approximately 12 months ]

Related Studies